John Nosenzo - 01 Apr 2022 Form 4 Insider Report for Bioventus Inc. (BVS)

Signature
/s/Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
01 Apr 2022
Net transactions value
-$1,251
Form type
4
Filing time
21 Apr 2023, 17:45:03 UTC
Previous filing
15 Feb 2022
Next filing
02 Jun 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Sale $563 -40 -0.05% $14.07 87,250 01 Apr 2022 Direct F1, F2
transaction BVS Class A Common Stock Sale $639 -95 -0.11% $6.73 87,155 01 Jul 2022 Direct F1
transaction BVS Class A Common Stock Sale $49 -7 -0.01% $7.00* 87,148 03 Oct 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reflects shares sold to cover taxes in connection with shares purchased under the Company's 2021 Employee Stock Purchase Plan.
F2 Includes an aggregate of 3,398 shares of Class A common stock purchased under the Company's 2021 Employee Stock Purchase Plan. This number has also been adjusted to account for a scrivener's error in a prior filing which attributed an acquisition of 40 shares under the Company's 2021 Employee Stock Purchase Plan.